| First Author | Robins DM | Year | 2008 |
| Journal | J Steroid Biochem Mol Biol | Volume | 108 |
| Issue | 3-5 | Pages | 230-6 |
| PubMed ID | 17936615 | Mgi Jnum | J:131199 |
| Mgi Id | MGI:3773135 | Doi | 10.1016/j.jsbmb.2007.09.002 |
| Citation | Robins DM, et al. (2008) Androgen receptor variants and prostate cancer in humanized AR mice. J Steroid Biochem Mol Biol 108(3-5):230-6 |
| abstractText | Androgen, acting via the androgen receptor (AR), is central to male development, differentiation and hormone-dependent diseases such as prostate cancer. AR is actively involved in the initiation of prostate cancer, the transition to androgen independence, and many mechanisms of resistance to therapy. To examine genetic variation of AR in cancer, we created mice by germ-line gene targeting in which human AR sequence replaces that of the mouse. Since shorter length of a polymorphic N-terminal glutamine (Q) tract has been linked to prostate cancer risk, we introduced alleles with 12, 21 or 48 Qs to test this association. The three 'humanized' AR mouse strains (h/mAR) are normal physiologically, as well as by cellular and molecular criteria, although slight differences are detected in AR target gene expression, correlating inversely with Q tract length. However, distinct allele-dependent differences in tumorigenesis are evident when these mice are crossed to a transgenic prostate cancer model. Remarkably, Q tract variation also differentially impacts disease progression following androgen depletion. This finding emphasizes the importance of AR function in androgen-independent as well as androgen-dependent disease. These mice provide a novel genetic paradigm in which to dissect opposing functions of AR in tumor suppression versus oncogenesis. |
